ResearchRSSMay 4
PAH treatment CPD1 shows promise in preclinical study
Researchers in China created a new drug called CPD1 that belongs to a class of medications called PDE5 inhibitors, which are already used to treat high blood pressure in the lungs (pulmonary arterial hypertension). In early testing on rats with this condition, CPD1 reduced disease severity and helped scientists understand how the drug works at a molecular level.
WHY IT MATTERSThis research identifies a potential new treatment option for PAH patients, though it remains in early preclinical stages and is years away from human testing or availability.